Navigating the Complexity of PAH: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, nurse practitioners, physician assistants, and pharmacists.
After completing this activity, the participant should be better able to:
- Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
- Interpret the results of recent trials for transition of PAH therapies
- Summarize real-world data from PAH registries and their potential implications for management
Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics
Stephan Rosenkranz, MD
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Merck Sharp & Dohme Corp.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is a knowledged-based activity. Universal Activity Numbers (UAN): #JA4008162-9999-21-2781-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period June 17, 2021 through June 17, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.